Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in Diffuse Cutaneous Systemic Sclerosis (Phase II)
2014-001353-16Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diffuse cutaneous systemic sclerosis (dcSSc) comparing Riociguat TID with Placebo (2 arms). Primary endpoint: Change in modified Rodnan Skin Score (mRSS) from baseline to Week 52. Started Oct 2014; status: completed.
02
Drugs
riociguat
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on 2014-001353-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001353-16.